1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the Market 26
2.2 Major Growth Drivers 28
2.3 Market Restraints and Challenges 33
2.4 Emerging Opportunities and Market Trends 36
2.5 Porters Fiver Forces Analysis 40
3 Segmentation of Global Market by Product Type 44
3.1 Market Overview by Product Type 44
3.2 Recombinant Non-glycosylated Biosimilars 46
3.2.1 Insulin 48
3.2.2 Recombinant Human Growth Hormone (rHGH) 49
3.2.3 Granulocyte Colony Stimulating Factor 50
3.2.4 Interferon 51
3.3 Recombinant Glycosylated Biosimilars 52
3.3.1 Monoclonal Antibodies (mAb) 53
3.3.2 Erythropoietin (EPO) 54
3.3.3 Follicle Stimulating Hormone 55
3.4 Recombinant Peptides and Others 56
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 57
3.4.2 Parathyroid Hormone 58
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 59
4 Segmentation of Global Market by Indication 60
4.1 Market Overview by Indication 60
4.2 Cancer 62
4.3 Autoimmune Disease 63
4.4 Blood Disorder 64
4.5 Diabetes 65
4.6 Growth Hormone Deficiency 66
4.7 Infectious Diseases 67
4.8 Other Indications 68
5 Segmentation of Global Market by Manufacturing 69
5.1 Market Overview by Manufacturing 69
5.2 Contract Manufacturing 71
5.3 Inhouse Manufacturing 72
6 Segmentation of Global Market by End User 73
6.1 Market Overview by End User 73
6.2 Hospitals and Clinics 75
6.3 Research Institutes 76
6.4 Other End Users 77
7 Segmentation of Global Market by Region 78
7.1 Geographic Market Overview 2019-2030 78
7.2 North America Market 2019-2030 by Country 82
7.2.1 Overview of North America Market 82
7.2.2 U.S. 86
7.2.3 Canada 96
7.2.4 Mexico 98
7.3 European Market 2019-2030 by Country 100
7.3.1 Overview of European Market 100
7.3.2 Germany 106
7.3.3 U.K. 108
7.3.4 France 110
7.3.5 Spain 112
7.3.6 Italy 114
7.3.7 Russia 116
7.3.8 Rest of European Market 118
7.4 Asia-Pacific Market 2019-2030 by Country 120
7.4.1 Overview of Asia-Pacific Market 120
7.4.2 Japan 124
7.4.3 China 127
7.4.4 Australia 129
7.4.5 India 131
7.4.6 South Korea 133
7.4.7 Rest of APAC Region 135
7.5 South America Market 2019-2030 by Country 137
7.5.1 Argentina 140
7.5.2 Brazil 142
7.5.3 Chile 144
7.5.4 Rest of South America Market 146
7.6 MEA Market 2019-2030 by Country 147
7.6.1 Turkey 150
7.6.2 Iran 152
7.6.3 South Africa 154
7.6.4 Other National Markets 156
8 Competitive Landscape 157
8.1 Overview of Key Vendors 157
8.2 New Product Launch, Partnership, Investment, and M&A 161
8.3 Company Profiles 162
AMEGA Biotech S.A. 162
Apotex Inc. 164
Biocon Ltd 165
Biogen Inc. 166
Boehringer Ingelheim 167
Celltrion, Inc. 168
Dr. Reddys Laboratories Ltd. 169
Eli Lilly and Company 170
Intas Pharmaceuticals Ltd. 171
LG Chem, Ltd. 172
Merck and Co. Inc. 173
Mylan N.V. 174
Pfizer Inc. 175
Samsung Biologics Co., Ltd. 176
Sandoz International GmbH 177
STADA Arzneimittel AG 178
Teva Pharmaceutical Industries Ltd. 179
RELATED REPORTS 180